The most important therapeutic effect of cholinesterase inhibitors (ChEI) on approximately
50% of Alzheimer's disease (AD) patients is to stabilize cognitive function at a steady level …

INTRODUCTION Alzheimer disease (AD) is a neurodegenerative disease affecting between
Solo and 10% of the population (1) over the age of 65. Individuals with AD exhibit profound …

Background: The presence of certain behavioral and psychological symptoms (eg, paranoia,
hallucinations, aggression, activity disturbances) in Alzheimer's disease (AD) may predict …

Parkinson's disease patients may suffer from cognitive impairment and behavioural
problems such as apathy, personality changes, speech disturbances and visual …

Cholinesterase inhibitors improve cognition and behaviour in some patients with
Alzheimer's disease (AD). Studies that have focused on methods to predict response to …

Background Cholinergic deficits are prominent in patients who have dementia associated
with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor …

Background: Cholinesterase inhibitors (ChEIs) are the only drugs marketed for the treatment
of Alzheimer's disease. Despite numerous randomized controlled trials, the efficacy and …

The current recommended standard of care for the symptomatic treatment of mild to
moderate Alzheimer's disease is cholinesterase inhibitors. In short-and long-term studies …

Alzheimer's Disease (AD) is characterized neurochemically by a profound loss of choline
acetyl transferase activity and histologically by a selective degeneration of cholinergic …

Background: We investigated the effect of cholinesterase inhibitors on all-cause
discontinuation, efficacy and safety, and the effects of study design-, intervention-, and …